As far as coronavirus plays go, the CytoDyn Inc (OTC: CYDY) stock has been one of the more popular ones and it is easy to see why.
The company has developed a product named leronlimab which is meant for treating patients who are suffering from COVID-19 infection. Last week, the stock recovered from its recent slump and went up by as high as 50%. However, it is also necessary to note that since hitting its peak in February, the stock is down by as low as 55%.
Last week the company announced that after analyzing the trial data from CD 12 and discussions with the United States Food and Drug Administration, it filed a new protocol for the product. The new protocol of the product is meant for extending treatment by four more weeks. CytoDyn believes that four weeks of treatment could be the optimum period for slowing down the cytokine storm.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.